LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis.
Journal Articles
Part of the Medicine and Health Sciences Commons
Part of the Medicine and Health Sciences Commons